Japan · Delayed Price · Currency is JPY Transgenic Group Company Description
Transgenic Group Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan.
It operates through Drug Discovery Support Business and Investment and Consulting Business segments. The company provides analysis of the function of individual genes in individuals, elucidation of the relationship between genes and pathology, production of disease model mice, gene expression analysis, and antibody production; clinical trials for pharmaceutical agents, such as bioequivalence studies; administrative services for clinical trials; clinical trials for foods for specified health uses; and hospital support.
It also conducts non-clinical studies for pharmaceuticals, medical devices, chemical substances, and food development using small and large animals.
In addition, the company offers services related to mergers and acquisitions, business revitalization, business succession, and investment business.
The company was formerly known as Trans Genic Inc. and changed its name to Transgenic Group Inc. in October 2024.
Transgenic Group Inc. was incorporated in 1998 and is headquartered in Fukuoka City, Japan.
| Country | Japan |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 227 |
| CEO | Kenji Fukunaga |
Contact Details
Address: 2-3-36 Tenjin Fukuoka City, 810-0001 Japan | |
| Phone | 81 9 2288 8470 |
| Website | transgenic-group.co.jp |
Stock Details
| Ticker Symbol | 2342 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3635720000 |
| SIC Code | 0200 |
Key Executives
| Name | Position |
|---|---|
| Kenji Fukunaga | Chief Executive Officer |
| Kazuo Watanabe | Chief Financial Officer |
| Yutaka Funabashi | Head of Investor Relations |